(Q73668650)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

The effect of sertraline on the pharmacokinetics of desipramine and imipramine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

1 reference

Kurtz DL

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Bergstrom RF

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Goldberg MJ

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Cerimele BJ

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 August 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

145-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Interaction between fluvoxamine and imipramine/desipramine in four patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Increased trimipramine plasma levels during fluvoxamine comedication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Clinical pharmacokinetics of imipramine and desipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

First-pass metabolism of imipramine in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

Sertraline 50 mg daily: the optimal dose in the treatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990062-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(97)90062-X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9284850%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference